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Substitution of the quantitative serological
component in the 2010 criteria for RA with
qualitative presence of three
autoantibodies yields similar performance:
response to the article by Regueiro et al.
Bastiaan T. van Dijk1* , Leendert A. Trouw1,2, Annette H. M. van der Helm-van Mil1,3 and Tom W. J. Huizinga1
Dear Editor,
Classification criteria are meant for research. Validation
of tests that measure individual components of criteria is
crucial for the primary goal of classification criteria,
namely that similar patients are included in scientific re-
search wherever in the world. Since the 2010 criteria for
RA were introduced, there have been concerns that send-
ing the same serum sample to different laboratories often
yields different levels [1], making the adjudication of
points to levels problematic. An alternative to levels is the
yes/no presence of autoantibodies which is supposed to be
more reliable between different laboratories. Therefore,
the recent report by Regueiro et al. is relevant. They re-
ported that qualitative testing of three RA autoantibodies
(including anti-CarP) demonstrated similar or slightly bet-
ter test results than the 2010 ACR/EULAR serological cri-
teria that incorporate quantitative results of ACPA and RF
testing [2].
To test whether the results of Regueiro et al. can be
replicated, we investigated the baseline serum samples of
patients from the Leiden Early Arthritis Clinic (Leiden-
EAC) from 1993 to February 2015. For the current ana-
lyses, we included patients newly presenting clinically
apparent arthritis with a clinical suspicion of RA or un-
differentiated arthritis (UA) at baseline, regardless of ful-
filment of classification criteria. Patients who at baseline
received an arthritis diagnosis other than RA or UA
were excluded. The Leiden-EAC is a Dutch inception
cohort including patients with clinical arthritis with a
symptom duration < 2 years at presentation, which has
been described previously [3]. The presence of RF,
ACPA and anti-CarP was determined as described previ-
ously; for anti-CarP, it concerned an in-house ELISA [4].
We compared test characteristics and odds ratios (ORs)
between the ACR/EULAR 2010 criteria, incorporating
quantitative results (levels) of ACPA and RF, and the
modified criteria using qualitative results (presence) of
anti-CarP, RF and ACPA (5 points for 3; 3 for 2; 1 for 1
concordant antibody/-ies, as proposed by Regueiro et al.)
while maintaining ≥ 6 points as the cut-off. Fulfilling the
1987 criteria after 1 year was used as the gold standard
for RA.
Of 2429 consecutive patients with a clinical suspicion
of RA or UA, 2010 had data on all three antibodies. Of
these, 2000 had 1-year follow-up data and were studied.
Test characteristics were found to be similar between
the ACR/EULAR 2010 and modified criteria (Table 1).
Most importantly, sensitivities were 84.5% (95% CI
82.4–86.7) and 82.3% (80.0–84.7), and specificities were
68.8% (65.9–71.7) and 71.6 (68.8–74.5), respectively.
In conclusion, we replicated the findings from Regueiro
et al. and observed that methodology based on qualitative
testing of anti-CarP, RF and ACPA yields similar test
characteristics as the original methodology based on
quantitative testing of RF and ACPA. Assuming that the
results will be similar when commercially available anti-
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CarP tests are done, and because auto-antibody levels are
more difficult to harmonise between different laboratories
[1], these results suggest that quantitative testing can pos-
sibly be replaced by qualitative testing.
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Table 1 Performance of the modified 2010 criteria (incorporating the concordance serological score proposed by Regueiro et al.)
compared to the original ACR/EULAR 2010 criteria for RA, with RA according to the 1987 criteria at 1 year as the gold standard
Serological component Sensitivity, % (95%CI) Specificity, % (95%CI) PPV, % (95%CI) NPV, % (95%CI) OR (95%CI)
2010 ACR/EULAR (quantitative) 84.5 (82.4–86.7) 68.8 (65.9–71.7) 74.9 (72.4–77.4) 80.2 (77.4–82.9) 12.1 (9.7–15.0)
Modified (qualitative) 82.3 (80.0–84.7) 71.6 (68.8–74.5) 76.2 (73.7–78.7) 78.7 (75.9–81.4) 11.8 (9.5–14.6)
PPV positive predictive value, NPV negative predictive value, OR odds ratio, CI confidence interval
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